Review Article
Treatment of Neuroendocrine Tumor Liver Metastases
Table 3
Summary of outcomes for intra-arterial therapy of neuroendocrine liver metastases.
| First author, publication year | Number of embolized patients | Survival data | Comments |
| Paprottka, 2011 [29] | 42 (90Y radioembolization) | 40 of 42 patients alive with mean followup of 16.2 months | No radiation-induced liver failure; 36 of 38 symptomatic patients improved clinically within 3 months |
| Kennedy, 2008 [30] | 148 (90Y radioembolization) | Median OS: 70 months | No radiation-induced liver failure |
| Strosberg, 2006 [31] | 84 (HAE) | Median OS: 36 months | Fewer symptoms in 44 of 55 symptomatic patients |
| Gupta, 2005 [32] | 123 (74 HAE, 49 HACE) | Median OS (carcinoid): 33.8 months Median OS (islet cell): 23.2 months | Male gender (versus female) predicted worse OS () for carcinoid, bone mets predicted worse OS for islet cell () |
| Dong, 2011 [33] | 123 (HACE) | Mean OS: 39.6 months 5-year OS: 36% 10-year OS: 20% | Baseline albumin <3.5 g/dL was multivariate predictor for poorer OS () |
|
|